Literature DB >> 9814819

Basic FGF and FGF receptor 1 are expressed in microglia during experimental autoimmune encephalomyelitis: temporally distinct expression of midkine and pleiotrophin.

X Liu1, G A Mashour, H F Webster, A Kurtz.   

Abstract

Heparin-binding growth factors have been implicated in central nervous system development, regeneration and pathology. To assess the expression pattern and possible function in multiple sclerosis, the heparin-binding growth factors pleiotrophin (PTN), midkine (MK), basic fibroblast growth factor (FGF-2) and one of its receptors (FGFR1/flg) mRNA and protein levels were examined in an experimental autoimmune encephalomyelitis (EAE) model in the Lewis rat. We assessed the time course of expression of PTN, MK and FGF-2 during EAE and determined the cellular origin of FGF-2 and FGFR1 in normal spinal cord and during inflammatory demyelination. Basal expression of PTN and MK mRNAs in normal spinal cords was significantly upregulated after induction of EAE. MK expression was upregulated two to threefold correlating with disease progression, whereas PTN expression reached peak levels threefold above basal levels during the clinical recovery period. FGF-2 mRNA expression was low in normal spinal cord and dramatically increased in correlation with progressive demyelination. FGF-2 was confined to neurons in normal tissue and shifted dramatically to microglia, paralleling their activation during EAE. Double immunohistochemistry revealed colocalization of FGF-2 to activated microglia/macrophages with strongest expression in the macrophage-rich perivascular core area and microglial expression at the edges of white and gray matter perivascular regions. FGFR1, like its ligand, was induced in activated macrophages/microglia. Growth factor expression in demyelinating diseases could serve several functions, e.g., to modulate the activity of microglia/macrophage in an autocrine fashion, to induce the expression of other factors like insulin-like growth factor 1 or plasminogen activator, which can effect regeneration or degeneration, respectively, and finally to stimulate directly localized proliferation and/or regeneration of oligodendrocytes within the lesion area.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9814819     DOI: 10.1002/(sici)1098-1136(199812)24:4<390::aid-glia4>3.0.co;2-1

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  32 in total

1.  Treatment of dry age-related macular degeneration with dobesilate.

Authors:  P Cuevas; L A Outeiriño; J Angulo; G Giménez-Gallego
Journal:  BMJ Case Rep       Date:  2012-06-21

2.  Oral administration of high molecular weight hyaluronan (900 kDa) controls immune system via Toll-like receptor 4 in the intestinal epithelium.

Authors:  Akira Asari; Tomoyuki Kanemitsu; Hitoshi Kurihara
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

Review 3.  The role of growth factors as a therapeutic approach to demyelinating disease.

Authors:  Yangyang Huang; Cheryl F Dreyfus
Journal:  Exp Neurol       Date:  2016-03-22       Impact factor: 5.330

4.  Anti-fibroblast growth factor-2 antibodies attenuate mechanical allodynia in a rat model of neuropathic pain.

Authors:  Francesca Madiai; Virginia M Goettl; Syed-Rehan Hussain; Alec R Clairmont; Robert L Stephens; Kevin V Hackshaw
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

5.  Retroviral lineage analysis of fibroblast growth factor receptor signaling in FGF2 inhibition of oligodendrocyte progenitor differentiation.

Authors:  Yong-Xing Zhou; Nicole C Flint; Joshua C Murtie; Tuan Q Le; Regina C Armstrong
Journal:  Glia       Date:  2006-11-01       Impact factor: 7.452

6.  Fibroblast growth factor signaling in oligodendrocyte-lineage cells facilitates recovery of chronically demyelinated lesions but is redundant in acute lesions.

Authors:  Miki Furusho; Aude J Roulois; Robin J M Franklin; Rashmi Bansal
Journal:  Glia       Date:  2015-04-22       Impact factor: 7.452

Review 7.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 8.  Midkine and multiple sclerosis.

Authors:  Hideyuki Takeuchi
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 9.  Whole brain radiation-induced vascular cognitive impairment: mechanisms and implications.

Authors:  Junie P Warrington; Nicole Ashpole; Anna Csiszar; Yong Woo Lee; Zoltan Ungvari; William E Sonntag
Journal:  J Vasc Res       Date:  2013-10-01       Impact factor: 1.934

10.  Midkine in vitamin D deficiency and its association with anti-Saccharomyces cerevisiae antibodies.

Authors:  F B Serinkan Cinemre; Hakan Cinemre; Cengiz Karacaer; Birsen Aydemir; Ahmet Nalbant; Tezcan Kaya; Ali Tamer
Journal:  Inflamm Res       Date:  2015-11-13       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.